- BioMérieux
- BD
- Danaher
- Thermo Fisher
- Bio-Rad Laboratories
- Hi-Media
- Merlin
- Liofilchem
- Accelerate
- Alifax
- Creative Diagnostics
- Merck Group
- Synbiosis
- Bioanalyse
- Zhuhai DL Biotech.
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Antimicrobial Susceptibility Testing Market:
In May 2022, NanoSynex Ltd., a business in which Qualigen recently finalised arrangements to acquire a controlling ownership, was highlighted at BioMed Israel, according to an announcement from Qualigen Therapeutics. Innovative technology developed by NanoSynex aims to six-fold accelerate the turnaround time for antimicrobial susceptibility test results.
The antimicrobial susceptibility testing (AST) market is dynamic and is influenced by various factors, such as the prevalence of infectious diseases, technological advancements, and government initiatives. One of the major factors influencing the growth of the AST market is the increasing incidence of infectious diseases worldwide. The emergence of new strains of drug-resistant bacteria and the increasing use of antibiotics has increased the demand for AST products and services. The development of new and advanced technologies is also driving the growth of the AST market. Advances in proteomics and genomics have led to the development of new diagnostic tools that can identify pathogens and their resistance mechanisms quickly and accurately. This has resulted in improved patient outcomes and reduced healthcare costs. Government initiatives and policies are also playing a critical role in the growth of the AST market. Several governments worldwide have implemented programs to promote the rational use of antibiotics and prevent the spread of antibiotic-resistant infections. These initiatives have led to increased demand for AST products and services.
However, the high cost of AST products and services remains a major challenge for the market. The high cost of these products and services limits their accessibility, particularly in low-income countries with a high burden of infectious diseases. Moreover, the lack of standardization in AST procedures and the emergence of new resistance mechanisms pose significant challenges for the market. Developing standardized testing procedures and implementing quality control measures are essential to ensure accurate and reliable results.
Overall, the AST market is dynamic, and it is anticipated to expand throughout the forecast period due to the rising prevalence of infectious illness, the development of new and innovative technologies, and government initiatives to promote the rational use of antibiotics. However, the market faces significant challenges that must be addressed to ensure its growth and sustainability.